IBS Treatment Market Research Report – Americas Forecast Till 2023


IBS Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) – Americas Forecast Till 2023

SKU: 190506 Categories: , Tag:


Market Analysis
Irritable bowel syndrome (IBS) is one of the major disorders affecting the digestive system of humans. Diarrhea, bloating, stomach cramps, and constipation, are some of the symptoms of the disorder. In spite of the fact that the reason for IBS is obscure, however, few factors that cause IBS are extreme disease, inflammation of the digestion tracts, contraction of muscles in the intestine, changes in gut bacteria, and nerve disorders. The rising pervasiveness of gastrointestinal infections and confusion, the geriatric populace, undesirable eating regimen, uneasiness, depression, and changing way of life in the Americas are the key drivers of the Americas IBS market. The Americas IBS treatment market is projected to grow at a CAGR of 9.3% during the forecast period 2017-2023.
Moreover, expanding consumer awareness about the IBS syndrome has increased the footfall of patient in the hospitals and other healthcare centers. Moreover, expanding expenditure in the medicinal services area is fueling the development of the IBS treatment market. However, strict FDA controls and inadmissible adequacy of the treatment may harm the development of the Americas IBS treatment market amid the forecast period (2017-2023).
Market Segmentation
The Americas IBS treatment market is segmented on the basis of its drugs type, types, end user and regional analysis. Based on its drugs type, the Americas IBS treatment market is sectioned into linaclotide, lubiprostone, eluxadoline, alosetron, rifaximin, and others. On the basis its types, the market is classified into IBS-C, IBS-D, IBS-M. Based on its end users, it is divided into clinics, research laboratories, and hospitals.
Regional Analysis
Geographically, the Americas IBS treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Major Players
The list of key players in Americas IBS treatment market include companies like Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Valeant Pharmaceuticals (Canada), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Ardelyx, Inc. (U.S.), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), Probi (Sweden), RedHill Biopharma Ltd. (Israel), Ipsen (France), AstraZeneca (U.K), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Takeda Pharmaceutical Company Ltd (Japan), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), 4D pharma plc (U.K), Innovate Biopharmaceuticals (U.S.), among others.

Table of Contents

Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Data points received from the doctors/ gastrologist:
3.1.3 Data points received from the manufacturer/ pharmaceutical companies:
3.1.4 Data points received from Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%)
4.2.2 Strong clinical pipeline (Impact Weightage: 35%)
4.2.3 Increasing prevalence of depression (Impact Weightage: 28%)
4.3 Restraints
4.3.1 Strict FDA regulations (Impact Weightage: 60%)
4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%)
4.4 Opportunity
4.5 Mega Trends
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Research and Development
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porters Five Forces
5.2.1 Threat of New Entrants (Medium to High)
5.2.2 Bargaining power of suppliers (Medium)
5.2.3 Threat of Substitutes (Medium to High)
5.2.4 Bargaining Power of Buyers (Medium)
5.2.5 Intensity of Rivalry (Medium to High)
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
6 Americas IBS Treatment Market, By Type
6.1 Introduction
6.2 IBS-D
6.3 IBS-C
6.4 IBS-M
7 Americas IBS Treatment Market, By Drug Type
7.1 Introduction
7.2 Lubiprostone
7.3 Linaclotide
7.4 Eluxadoline
7.5 Rifaximin
7.6 Alosetron
8 Americas IBS Treatment Market, By End User
8.1 Introduction
8.2 Hospitals
8.3 Clinics
8.4 Research laboratories
9 Americas IBS treatment By Region
9.1 Introduction
9.1.1 North America U.S. Canada
9.1.2 South America
10 Company Landscape
11 Company Profiles
11.1 Allergan Plc
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Sucampo Pharmaceuticals
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Ironwood Pharmaceuticals, Inc.
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 Astellas Pharma Inc.
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Valeant Pharmaceuticals
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Abbott Laboratories
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Synergy Pharmaceuticals, Inc.
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
11.8 Ardelyx, Inc.
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Nestle
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.1 Sebela Pharmaceuticals
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 Probi
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Strategy
11.11.5 Key Developments
11.12 Alfasigma USA, Inc.
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Strategy
11.12.5 Key Developments
12 Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs
12.2 Key Companies to Watch
13 Appendix
13.1 Discussion Blue Print

Additional information


Geography Covered

Date Published